SAN DIEGO (AP) ¿ Cadence Pharmaceuticals Inc. said Thursday its fourth-quarter loss narrowed slightly on lower research and development expenses. The company lost $14 million, or 37 cents per share, compared with a loss of $14.2 million, or 50 cents per share, during the same period a year prior. Shares outstanding jumped to 38.2 million in the recent quarter from 28.7 million in the year-ago period. There was no revenue recorded in either quarter. Analysts polled by Thomson Reuters expected a loss of 36 cents per share. Operating costs fell to $13.5 million from $14.6 million. The company also said it cut development of Omigard, which was aimed at treating catheter-related infections. It expects operating expenses to fall in 2009 without that program. Shares of Cadence Pharmaceuticals gained 20 cents, or 3.3 percent, to close at $6.20.